Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,989Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Abstract

LUX-Lung 6 compared afatinib with cisplatin/gemcitabine in Asian patients with EGFR mutation-positive advanced NSCLC.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(13)70604-1

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

19 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 37 references

Research works printed but not linked: 1

  1. 2003, Ann Oncol, 14, 345

Cited by

See all 1,989

Metadata

Authors
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., Xu, C.-R., Massey, D., Kim, M., Shi, Y., & Geater, S. L.
Affiliations
  • Guangdong General Hospital (CN)
  • Shanghai Pulmonary Hospital (CN)
  • Jiangsu Cancer Hospital (CN)
  • Kunming Medical University (CN)
  • Sichuan University (CN)
  • Konkuk University Medical Center (KR)
  • Boehringer Ingelheim (United Kingdom) (GB)
  • Boehringer Ingelheim (South Korea) (KR)
  • Boehringer Ingelheim (China) (CN)
  • Prince of Songkla University (TH)
Corresponding author
Wu, Yi-Long
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2014-02
Volume
15
Issue
2
Pages
213-222
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2171139285
Cited by
1,978
References
37
Citations by year
2026: 39 · 2025: 77 · 2024: 97 · 2023: 107 · 2022: 169 · 2021: 205 · 2020: 168 · 2019: 211 · 2018: 216 · 2017: 203 · 2016: 194 · 2015: 204 · 2014: 82
FWCI
182.59
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
afatinib, EGFR-mutant non-small cell lung cancer, first-line therapy, gemcitabine plus cisplatin, progression-free survival, Asian patients, EGFR tyrosine kinase inhibitors, EGFR exon 19 deletion, treatment-related adverse events, pemetrexed
MeSH terms
Afatinib, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, China, Cisplatin, Deoxycytidine, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Quinazolines, Risk Factors, Thailand, Time Factors, Linear Models, Logistic Models, Proportional Hazards Models, Odds Ratio, Treatment Outcome, Disease Progression, Disease-Free Survival, Asian People, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Republic of Korea, Intention to Treat Analysis, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(13)70604-1
The paper
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., Xu, C.-R., Massey, D., Kim, M., Shi, Y., & Geater, S. L. (2014). Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(13)70604-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.